The US-based Albany Molecular Research Inc (AMRI), a global contract research and
manufacturing organisation, has acquired the outstanding equity
interests of Aptuit's Glasgow, UK, business and has entered into a
definitive agreement to acquire Aptuit's SSCI/West Lafayette (Indiana,
USA) business for total consideration of $60 million, expanding AMRI's
drug product development and aseptic clinical manufacturing
capabilities.
Servicing more than 250 customers a year, SSCI is known for solving difficult drug substance and formulated drug product challenges and is an expert in solid-state chemistry and analytical services. In addition, Aptuit's Glasgow facility will extend AMRI's capabilities platform to include sterile injectable drug product formulation and clinical stage manufacturing.
“We are very pleased to acquire these two facilities from Aptuit, which will further AMRI's expertise in drug product development and aseptic manufacturing services, two areas of our business where we are seeing the fastest level of growth,” said William Marth, AMRI's president and chief executive officer.
Servicing more than 250 customers a year, SSCI is known for solving difficult drug substance and formulated drug product challenges and is an expert in solid-state chemistry and analytical services. In addition, Aptuit's Glasgow facility will extend AMRI's capabilities platform to include sterile injectable drug product formulation and clinical stage manufacturing.
“We are very pleased to acquire these two facilities from Aptuit, which will further AMRI's expertise in drug product development and aseptic manufacturing services, two areas of our business where we are seeing the fastest level of growth,” said William Marth, AMRI's president and chief executive officer.
No comments:
Post a Comment